Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab for relapsing bullous pemphigoid
2006-005744-92Phase 3Active
- Sponsor
- Rouen University Hospital
- Start
- Mar 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of rituximab in Bullous Pemphigoid (BP), sponsored by Rouen University Hospital. Primary endpoint: Complete remission at 3 months. Started Mar 2007; status: active.
02
Drugs
rituximab
03
Conditions
Bullous Pemphigoid (BP)
Beyond the preview
Go deeper on 2006-005744-92.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005744-92.